Asthma's hidden switch: scientists hunt for calcium channels in Kids' immune cells

NCT ID NCT02809560

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 ยท Last updated Sep 21, 2026

Summary

Researchers want to know whether certain calcium channels, called Cav1, appear on the immune cells of children with allergic asthma. These channels normally sit on nerve and muscle cells, but earlier animal work hinted they might also show up on the T cells that fuel asthma inflammation. The study collects sputum and blood samples from about 60 asthmatic children and compares them with samples from children without asthma. The goal is to see if Cav1 channels are present and whether they are more common in asthmatic children, which could point to a new treatment target.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
induced sputum collection using hypertonic saline
What this could lead to
If researchers find Cav1 channels on the immune cells that drive asthma, this could point toward new drugs that target those channels to calm airway inflammation.
What could go wrong
This is an early lab-based study with 60 children, so it may not confirm that Cav1 channels play a meaningful role in asthma. Even if it does, any treatment based on the finding would be years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Start date

Mar 2013

Finished

May 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For Asthmatic children arm : * Girl not in childbearing potential or taking contraceptive treatment * Asthma diagnosis in at least 6 months as defined by clinical symptoms (expiratory dyspnea, wheezing, sibilance) and respiratory function (reversibility of VEMS at least 12% after salbutamol administration) * Allergologic tests positives to airborne allergens : positive prick test and/or specific IgE \> 0,35 kU/L for at least one allergen * Asthma severity between mild to moderate based on Global initiative for asthma classification during more than one month with inhaled corticotherapies +/- long term action beta -mimetic long compounds (salmeterol, formoterol) * Patient insured with a social security scheme For control children arm : * Girl not in childbearing potential or taking contraceptive treatment * No medical history of asthma * No medical history of allergy or symptoms of allergy on skin (atopic dermatitis), respiratory tract (rhino-conjunctivitis, asthma) or food allergy Exclusion Criteria: For both arms: * Chronic respiratory pathology : known occlusive or restrictive respiratory syndrome like interstitial lung disease, neuromuscular disease, mucoviscidoses, respiratory tract abnormalities with cough, dyspnea or digital hippocratism. * History of pulmonary or nose and throat infectious disease during last 4 months * Parasitic disease non treated during last 3 months * Dyspnea during the inclusion * Systemic corticotherapy during the last 3 months before inclusion * Immunosuppressive therapy during the last 3 months before inclusion * Diabeta * Disease causing immune disorder * Infection during inclusion * Participation to another study witch implies medical treatment during last 3 months before inclusion For asthmatic children arm : * Chronic pulmonary pathology (excluding asthma) * Asthma exacerbation during inclusion * VEMS \< 70% of normal range or VEMS \< 70% of normal range after inhalation of serum (despite salbutamol administration) * Patient unable to complete pulmonary function testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.